What is the survival rate for leukemia patients? What is the survival rate for kidney cancer? What is the survival rate of cervical cancer stage 2? How fast does anaplastic thyroid cancer grow? How fast does follicular thyroid cancer grow?
BackgroundChronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) are highly treatable conditions occurring primarily in older patients. Lower survival among older people has been reported in both conditions, but newer treatments may change both the overall survival rate and the relative ...
All the methods and their estimators are illustrated on a sub-cohort of older patients who received a first allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes or secondary acute myeloid leukemia, to show how different methods can provide different insights into the data. ...
In 46 patients receiving allogeneic hematopoietic cell transplantation (0.8%), the median survival from diagnosis was 22 months.Therapy for leukemia improves overall survival in older acute myeloid leukemia patients. Based on their comorbidities, most patients up to 80 years of age should be ...
35-45 Patients with non–small cell tumors are usually treated surgically, but only 30% of these patients can be operated on with a curative intention. If resection is not possible, the tumor can be irradiated. Small cell tumors have an especially high rate of malignancy. The median survival...
Angelo de Claro, MD; Richard Pazdur, MD JAMA Oncology Podcast (13:59) Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia 1x 0:00 / 0:00 Subscribe to Podcast Key Points Question What is the association between measurable residual disease (MRD) and...
Acute myeloid leukemia (AML) is a very heterogeneous and highly malignant blood cancer. Mutations of the DNA methyltransferase DNMT3A are among the most frequent recurrent genetic lesions in AML. The majority of DNMT3A-mutant AML patients shows fast rela
No statistical heterogeneity was found (Q-test:p=.888;I2=0%). The pooled results with fixed effects models showed a favorable disease-free survival hazard rate for p16-positive patients compared to p16-negative (n=3; HR=0.351; 95% CI 0.225 to 0.548;p<.001) (Fig. 5). ...
Survival RateAnalysis of VarianceRetrospective StudiesWhen the novel agents thalidomide, bortezomib and lenalidomide are administered to patients with myeloma in the context of clinical trials, they are associated with a significant improvement in response, progression-free survival and in some studies, ...
The annual death-rate of the patients with acute lymphoblastic leukmia (A.L.L.) fell from about 25% in the fifth and sixth years to 6% thereafter; no patient died after the tenth year. Evidence of a low total leukmic-cell mass was more commonly found at diagnosis of patients with A....